LoginRegister
    US government seeks part of Oklahoma $270 million opioid settlementUS government seeks part of Oklahoma $270 million opioid settlement
    Former USFDA boss Scott Gottlieb to join Pfizer boardFormer USFDA boss Scott Gottlieb to join Pfizer board
    Coming Soon: Common Drug license management for all states via One single software platformComing Soon: Common Drug license management for all states via One single software platform
    USFDA Warning: Medtronic recalls insulin pumps over cybersecurity vulnerabilitiesUSFDA Warning: Medtronic recalls insulin pumps over cybersecurity vulnerabilities
    Stop use of trademark deceptively similar to Glaxo antibiotic Augmentin: Delhi High Court to AFDILStop use of trademark deceptively similar to Glaxo antibiotic Augmentin: Delhi High Court to AFDIL
    Alembic Pharma clears USFDA inspection at oncology unit in PanelavAlembic Pharma clears USFDA inspection at oncology unit in Panelav
    Regeneron Pharma gets USFDA nod for Dupixent to treat rhinosinusitis with nasal polypsRegeneron Pharma gets USFDA nod for Dupixent to treat rhinosinusitis with nasal polyps
    Drug marketers as liable as Drug Manufacturers for quality, efficacy, regulatory compliance: Health Ministry Issues DraftDrug marketers as liable as Drug Manufacturers for quality, efficacy, regulatory compliance: Health...
    Glenmark Pharma receives USFDA approval for generic version of Vytorin tabletsGlenmark Pharma receives USFDA approval for generic version of Vytorin tablets
    Sun Pharma enters licensing agreement with CMS for arthritis drug TildrakizumabSun Pharma enters licensing agreement with CMS for arthritis drug Tildrakizumab
    Lupin gets tentative USFDA nod for generic version of Mirabegron ER tabletsLupin gets tentative USFDA nod for generic version of Mirabegron ER tablets
    Bayer contested Glyphosate use will eventually end, says German ChancellorBayer contested Glyphosate use will eventually end, says German Chancellor
    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

    © 2025 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X